Duijvestein, Marjolijn
Battat, Robert
Vande Casteele, Niels
D’Haens, Geert R.
Sandborn, William J.
Khanna, Reena
Jairath, Vipul
Feagan, Brian G.
Article History
First Online: 6 February 2018
Compliance with Ethical Standards
:
: Robert Battat declares no conflict of interest.Marjolijn Duijvestein reports nonfinancial support from Dr. Falk Pharma and personal fees from Janssen, Merck & Co., Inc., Pfizer, and Tillotts Pharam.Niels Vande Casteele reports personal fees from Janssen, Pfizer, Takeda, UCB Pharma, and Boehringer Ingelheim.Geert R. D’Haens reports grants from Photophill and grants and personal fees from Abbvie, Ferring, Dr. Falk Pharma, Johnson and Johnson, Millenium/Takeda, MSD, Mundipharma, and Prometheus laboratories/Nestle.Dr. D’Haens also received personal fees from Ablynx, Amaken, Amgen, AM Pharma, Avaxia, Biogen, BMS, Celgene, Boerhinger Ingelheim, Celltrion, Cosmo, Covidien/Medtronics, Eli Lilly, Engene, Galapagos, Genentech/Roche, GSK, Gilead, Lycera, Medimetrics, MitsubishiPharma, Nextbiotics, Novonordisk, Norgine, Otsuka, Pfizer, Protagonist, Receptos/Celgene, Salix, Sandoz, Setpoint, Shire, TEVA, Tigenix, Tillotts, Versant, and Vifor.William J. Sandborn reports personal fees and nonfinancial support from Robarts Clinical Trials (wholey owned by Western University, London, Ontario, Canada). Dr. Sandborn has also received grants and personal fees from Prometheus Laboratories, AbbVie, Boehringer Ingelheim, Takeda, Atlantic Pharmaceuticals, Janssen, Bristol-Myers Squibb, Genentech, and Nutrition Science Partners and personal fees from Kyowa Hakko Kirin, Millennium Pharmaceuticals, Celgene Cellular Therapeutics, Santarus, Salix Pharmaceuticals, Catabasis Pharmaceuticals, Vertex Pharmaceuticals, Warner Chilcott, Gilead Sciences, Cosmo Pharmaceuticals, Ferring Pharmaceuticals, Sigmoid Biotechnologies, Tillotts Pharma, Am Pharma BV, Dr. August Wolff, Avaxia Biologics, Zyngenia, Ironwood Pharmaceuticals, Index Pharmaceuticals, Nestle, Lexicon Pharmaceuticals, UCB Pharma, Orexigen, Luitpold Pharmaceuticals, Baxter Healthcare, Ferring Research Institute, Amgen, Novo Nordisk, Mesoblast Inc., Shire, Ardelyx Inc., Actavis, Seattle Genetics, MedImmune (AstraZeneca), Actogenix NV, Lipid Therapeutics Gmbh, Eisai, Qu Biologics, Toray Industries Inc., Teva Pharmaceuticals, Eli Lilly, Chiasma, TiGenix, Adherion Therapeutics, Immune Pharmaceuticals, Celgene, Arena Pharmaceuticals, Ambrx Inc., Akros Pharma, Vascular Biogenics, Theradiag, Forward Pharma, Regeneron, Galapagos, Seres Health, Ritter Pharmaceuticals, Theravance, Palatin, and Biogen. In addition, Dr. Sandborn has a patent Topical azathioprine to treat inflammatory bowel disorders (US 5,691,343) issued, a patent Topical formulations of azathioprine to treat inflammatory bowel disorders (US 5,905,081) issued, a patent Colonic delivery of nicotine to treat inflammatory bowel disease (South African patent 97/1020; US 5,846,983, 5,889,028, and 6,166,044; Mexico patent 209,636; Europe patents 0954337 and 893,998; Hong Kong patent HK1019043; China patent ZL97192177; Czech patent 293,616; Canada patent 2,246,235) issued, a patent The use of azathioprine to treat Crohn’s disease (US 5,733,915) issued, a patent Azathioprine compositions for colonic administration (New Zealand patent 306062; Singapore patent 45647; Australia patent 707168; Czech patent 290428) issued, a patent Intestinal absorption of nicotine to treat nicotine responsive conditions (Australia patent 718052; US 6,238,689) issued, a patent The use of topical azathioprine and thioguanine to treat colorectal adenomas (US 6,166,024) issued, a patent Enema and enterically coated oral dosage forms of azathioprine (US 6,432,967) issued, a patent A pharmaceutical composition for the treatment of inflammatory bowel disease (US 7,341,741) issued, a patent Intestinal absorption of nicotine to treat nicotine responsive conditions (Canada patent 2,260,909) issued, and a patent Obesity treatment and device (US 7,803,195 B2) licensed to Enteromedics.Reena Khanna reports personal fees from AbbVie, Janssen, Pfizer, Shire, and Takeda.Vipul Jairath reports personal fees from Janssen, Takeda, Abbvie, Ferring, and Pfizer.Brian G. Feagan reports grants and personal fees from AbbVie, Amgen, Astra Zeneca, Bristol-Meyers Squibb (BMS), Janssen Biotech/Centocor, JnJ/Janssen, Pfizer, Receptos, and Takeda. Dr. Feagan also reports personal fees from Actogenix, Akros, Albireo Pharma, Allergan, Avaxia Biologics Inc., Avir Pharma, Atlantic Pharma, Baxter Healthcare Corporation, Biogen Idec, Boehringer-Ingelheim, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring, Genentech/Roche, GiCare Pharma, Gilead, Given Imaging, GSK, Ironwood, Kyowa Kakko Kirin Co Ltd., Lilly, Lycera Biotech, Merck, Mesoblast Pharma, Millennium, Nestles, Novo Nordisk, Novartis, Prometheus Therapeutics & Diagnostics, Protagonist, Salix, Shire, Sigmoid Pharma, Synergy Pharma, Teva Pharma, TiGenix, Tillotts, UCB, Vertex, VHsquared, Wyeth, Zealand, Zyngenia, Galapagos, Inception IBD Inc., Lexicon, Vivelix Pharma, Japan Tobacco Company, Ablynx, Progenity, and NextBiotix. Dr. Feagan has also received a grant from Sanofi and is Senior Scientific Officer, Robarts Clinical Trials Inc., Western University, London, Ontario, Canada.
: This article does not contain any studies with human or animal subjects performed by any of the authors.